Risk and Consequences of Chemotherapy-induced Neutropenic Complications in Patients Receiving Daily Filgrastim: the Importance of Duration of Prophylaxis

Overview

Journal BMC Health Serv Res

Publisher Biomed Central

Specialty Health Services

Date 2014 Apr 29

PMID 24767095

Citations 19

Authors

Derek Weycker

Rich Barron

John Edelsberg

Alex Kartashov

Jason Legg

Andrew G Glass

Affiliations

Soon will be listed here.

Abstract

Background: To examine duration of daily filgrastim prophylaxis, and risk and consequences of chemotherapy-induced neutropenic complications (CINC) requiring inpatient care.

Methods: Using a retrospective cohort design and US healthcare claims data (2001-2010), we identified all cancer patients who initiated ≥1 course of myelosuppressive chemotherapy and received daily filgrastim prophylactically in ≥1 cycle. Cycles with daily filgrastim prophylaxis were pooled for analyses. CINC was identified based on hospital admissions with a diagnosis of neutropenia, fever, or infection; consequences were characterized in terms of hospital mortality, hospital length of stay (LOS), and CINC-related healthcare expenditures.

Results: Risk of CINC requiring inpatient care-adjusted for patient characteristics-was 2.4 (95% CI: 1.6-3.4) and 1.9 (1.3-2.8) times higher with 1-3 (N = 8371) and 4-6 (N = 3691) days of filgrastim prophylaxis, respectively, versus ≥7 days (N = 2226). Among subjects who developed CINC, consequences with 1-3 and 4-6 (vs. ≥7) days of filgrastim prophylaxis were: mortality (8.4% [n/N = 10/119] and 4.0% [3/75] vs. 0% [0/34]); LOS (means: 7.4 [N = 243] and 7.1 [N = 99] vs. 6.5 [N = 40]); and expenditures (means: $18,912 [N = 225] and $14,907 [N = 94] vs. $13,165 [N = 39]).

Conclusions: In this retrospective evaluation, shorter courses of daily filgrastim prophylaxis were found to be associated with an increased risk of CINC as well as poorer outcomes among those developing this condition. Because of the limitations inherent in healthcare claims databases specifically and retrospective evaluations generally, additional research addressing these limitations is needed to confirm the findings of this study.

Citing Articles

Drug-induced pneumonitis risk in diffuse large B-cell/follicular lymphoma patients treated with R-CHOP-like regimen is associated with the use of granulocyte colony-stimulating growth factors.

Kaprio E, Prusila R, Tokola S, Kuusisto M, Jantunen E, Kuitunen H Cancer Med. 2024; 13(1):e6898.

PMID: 38164067 PMC: 10807566. DOI: 10.1002/cam4.6898.

Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.

Aapro M, Chaplin S, Cornes P, Howe S, Link H, Koptelova N Support Care Cancer. 2023; 31(10):581.

PMID: 37728795 PMC: 10511548. DOI: 10.1007/s00520-023-08043-4.

Prescription patterns of granulocyte colony-stimulating factors in patients with breast cancer: A real-world study.

Hsu S, Chiang S, Hsu J, Ko Y PLoS One. 2023; 18(7):e0288642.

PMID: 37459309 PMC: 10351717. DOI: 10.1371/journal.pone.0288642.

Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis.

Aslam S, Li E, Bell E, Lal L, Anderson A, Peterson-Brandt J J Manag Care Spec Pharm. 2023; 29(2):128-138.

PMID: 36705281 PMC: 10387928. DOI: 10.18553/jmcp.2023.29.2.128.

The Real-World Experience of the Biosimilar (Grastofil) to the Reference Biologic (Neupogen) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study.

Wong G, Wang K, Pasetka M, Zhang L, Lou J, Majeed H Curr Oncol. 2022; 29(3):1349-1369.

PMID: 35323315 PMC: 8947031. DOI: 10.3390/curroncol29030115.

References

Caggiano V, Weiss R, Rickert T, Linde-Zwirble W . Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005; 103(9):1916-24. DOI: 10.1002/cncr.20983. View

Smith T, Khatcheressian J, Lyman G, Ozer H, Armitage J, Balducci L . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19):3187-205. DOI: 10.1200/JCO.2006.06.4451. View

Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L . Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2008; 12(12):1416-24. DOI: 10.1634/theoncologist.12-12-1416. View

Vogel C, Wojtukiewicz M, Carroll R, Tjulandin S, Barajas-Figueroa L, Wiens B . First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005; 23(6):1178-84. DOI: 10.1200/JCO.2005.09.102. View

Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G . Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol. 2011; 35(3):267-74. DOI: 10.1097/COC.0b013e31820dc075. View

Kuderer N, Dale D, Crawford J, Cosler L, Lyman G . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106(10):2258-66. DOI: 10.1002/cncr.21847. View

Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A . Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2007; 87(4):277-83. DOI: 10.1007/s00277-007-0399-y. View

Groessl E, Kaplan R, Cronan T . Quality of well-being in older people with osteoarthritis. Arthritis Rheum. 2003; 49(1):23-8. DOI: 10.1002/art.10903. View

Green M, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P . A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2002; 14(1):29-35. DOI: 10.1093/annonc/mdg019. View

10.

Rajan S, Lyman G, Stearns S, Carpenter W . Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. Med Care. 2011; 49(7):649-57. DOI: 10.1097/MLR.0b013e318215c42e. View

11.

Weycker D, Barron R, Edelsberg J, Kartashov A, Lyman G . Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat. 2012; 133(1):301-10. DOI: 10.1007/s10549-011-1949-5. View

12.

Rivera E, Smith Jr R . Trends in recommendations of myelosuppressive chemotherapy for the treatment of breast cancer: evolution of the national comprehensive cancer network guidelines and the cooperative group studies. Clin Breast Cancer. 2006; 7(1):33-41. DOI: 10.3816/CBC.2006.n.011. View

13.

Weycker D, Hackett J, Edelsberg J, Oster G, Glass A . Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?. Ann Pharmacother. 2006; 40(3):402-7. DOI: 10.1345/aph.1G516. View

14.

Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991; 325(3):164-70. DOI: 10.1056/NEJM199107183250305. View

15.

Lyman G, Michels S, Reynolds M, Barron R, Tomic K, Yu J . Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010; 116(23):5555-63. DOI: 10.1002/cncr.25332. View

16.

Bonadonna G, Moliterni A, Zambetti M, Daidone M, Pilotti S, Gianni L . 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005; 330(7485):217. PMC: 546063. DOI: 10.1136/bmj.38314.622095.8F. View

17.

Romieu G, Clemens M, Mahlberg R, Fargeot P, Constenla M, Schutte M . Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol. 2007; 64(1):64-72. DOI: 10.1016/j.critrevonc.2006.12.007. View

18.

Smith R . Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. J Natl Compr Canc Netw. 2006; 4(7):649-58. DOI: 10.6004/jnccn.2006.0056. View

19.

Hecht J, Pillai M, Gollard R, Heim W, Swan F, Patel R . A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010; 9(2):95-101. DOI: 10.3816/CCC.2010.n.013. View

20.

Gruschkus S, Lairson D, Dunn J, Risser J, Du X . Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy. J Am Geriatr Soc. 2010; 58(10):1885-95. PMC: 6336678. DOI: 10.1111/j.1532-5415.2010.03081.x. View